PYPD
PolyPid Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$5.14
+2.19%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$5.12
From 52W high−7.89%
Volume62735.00
Market cap$104.40M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$5.12
From 52W high
−7.89%
Volume
62735.00
Market cap
$104.40M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.2x
P/E (TTM)
—
RSI (14)
52.8
MomentumView details →
1D Return
+2.19%
YTD Return
+18.89%
SummaryUpdated Jun 1, 2026
PolyPid Ltd. (NASDAQ:PYPD) is an Israeli late-stage biopharmaceutical company founded in 2008 and headquartered in Petah Tikva, Israel. The company went public in June 2020 and focuses on developing innovative drug delivery solutions using its proprietary polymer-lipid encapsulation matrix (PLEX) platform technology. PolyPid is currently in Phase III clinical trials with its lead product candidate D-PLEX100, designed to prevent surgical site infections, representing a significant unmet medical need in healthcare settings.
Similar companies
Latest newsMore news →
No recent news for PYPD.